RGEN: Repligen Corporation
RGEN exchange rate has changed by -1.19% for today. During the day, the instrument was traded at a low of 165.00 and at a high of 169.50.
Follow Repligen Corporation dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
RGEN News
- ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
- Software Rebound Extends Moat Index Gains
- Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
- TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
- QURE Submits Application for Gene Therapy for Huntington's Disease
- Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
- Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
- GSK to Advance mRNA Influenza Vaccine Into Phase III Development
- OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
- Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
- JAZZ Rises on Updated OS Results From Gastric Cancer Study
- Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
- Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
- ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
- Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?
- Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
- 5 Biotech Stocks Worth Adding to Your Portfolio Now
- J&J's Imaavy Gets FDA Approval as the First Treatment for wAIHA
- GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
- Acadia Gets European Commission Nod for Daybu in Rett Syndrome
- HALO Stock Rises 36% in a Month: Here's What You Should Know
- Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
- MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win
- RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
Frequently Asked Questions
What is RGEN stock price today?
Repligen Corporation stock is priced at 167.60 today. It trades within 165.00 - 169.50, yesterday's close was 169.61, and trading volume reached 1942. The live price chart of RGEN shows these updates.
Does Repligen Corporation stock pay dividends?
Repligen Corporation is currently valued at 167.60. Dividend policy depends on the company, while investors also watch 1.15% and USD. View the chart live to track RGEN movements.
How to buy RGEN stock?
You can buy Repligen Corporation shares at the current price of 167.60. Orders are usually placed near 167.60 or 167.90, while 1942 and 1.02% show market activity. Follow RGEN updates on the live chart today.
How to invest into RGEN stock?
Investing in Repligen Corporation involves considering the yearly range 100.99 - 188.73 and current price 167.60. Many compare -6.54% and 41.39% before placing orders at 167.60 or 167.90. Explore the RGEN price chart live with daily changes.
What are Repligen Corporation stock highest prices?
The highest price of Repligen Corporation in the past year was 188.73. Within 100.99 - 188.73, the stock fluctuated notably, and comparing with 169.61 helps spot resistance levels. Track Repligen Corporation performance using the live chart.
What are Repligen Corporation stock lowest prices?
The lowest price of Repligen Corporation (RGEN) over the year was 100.99. Comparing it with the current 167.60 and 100.99 - 188.73 shows potential long-term entry points. Watch RGEN moves on the chart live for more details.
When did RGEN stock split?
Repligen Corporation has gone through stock splits historically. These changes are visible in , 169.61, and 1.15% after corporate actions.
- Previous Close
- 169.61
- Open
- 165.90
- Bid
- 167.60
- Ask
- 167.90
- Low
- 165.00
- High
- 169.50
- Volume
- 1.942 K
- Daily Change
- -1.19%
- Month Change
- -6.54%
- 6 Months Change
- 41.39%
- Year Change
- 1.15%